Commonwealth Equity Services LLC Reduces Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Commonwealth Equity Services LLC trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 4.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 100,441 shares of the company’s stock after selling 4,930 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Moderna were worth $23,601,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Baillie Gifford & Co. increased its stake in shares of Moderna by 1.2% during the second quarter. Baillie Gifford & Co. now owns 45,883,213 shares of the company’s stock valued at $10,781,638,000 after purchasing an additional 545,449 shares in the last quarter. Morgan Stanley raised its holdings in Moderna by 41.9% in the 1st quarter. Morgan Stanley now owns 8,222,788 shares of the company’s stock worth $1,076,775,000 after purchasing an additional 2,427,704 shares during the period. Theleme Partners LLP lifted its stake in shares of Moderna by 17.9% during the 1st quarter. Theleme Partners LLP now owns 6,302,056 shares of the company’s stock valued at $825,254,000 after buying an additional 958,358 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Moderna by 6.6% during the first quarter. Geode Capital Management LLC now owns 3,806,430 shares of the company’s stock worth $497,852,000 after acquiring an additional 235,190 shares during the last quarter. Finally, Banque Pictet & Cie SA increased its position in Moderna by 0.6% in the first quarter. Banque Pictet & Cie SA now owns 3,039,409 shares of the company’s stock worth $398,011,000 after purchasing an additional 19,400 shares during the last quarter. Hedge funds and other institutional investors own 55.89% of the company’s stock.

A number of analysts have weighed in on the company. Jefferies Financial Group upped their target price on Moderna from $170.00 to $250.00 and gave the stock a “hold” rating in a report on Thursday, July 15th. They noted that the move was a valuation call. Argus increased their target price on shares of Moderna from $200.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, June 24th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 5th. Morgan Stanley boosted their target price on Moderna from $190.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 7th. Finally, Piper Sandler downgraded shares of Moderna from an “overweight” rating to a “neutral” rating in a research note on Friday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $205.21.

NASDAQ MRNA opened at $430.14 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.24. The stock has a market cap of $173.62 billion, a PE ratio of 53.63, a P/E/G ratio of 0.52 and a beta of 1.48. The firm has a 50-day moving average of $396.12 and a 200-day moving average of $254.15. Moderna, Inc. has a 52-week low of $65.49 and a 52-week high of $497.49.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 5th. The company reported $6.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $6.01 by $0.45. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.23 billion. Moderna had a net margin of 49.79% and a return on equity of 88.13%. During the same quarter in the previous year, the company earned ($0.31) EPS. The company’s revenue for the quarter was up 6457.2% on a year-over-year basis. As a group, analysts predict that Moderna, Inc. will post 29.17 EPS for the current fiscal year.

In related news, insider Juan Andres sold 5,000 shares of the firm’s stock in a transaction on Tuesday, July 6th. The shares were sold at an average price of $229.62, for a total transaction of $1,148,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Stephen Hoge sold 10,000 shares of the firm’s stock in a transaction on Tuesday, July 6th. The stock was sold at an average price of $229.62, for a total value of $2,296,200.00. Following the completion of the sale, the president now owns 1,619,597 shares of the company’s stock, valued at $371,891,863.14. The disclosure for this sale can be found here. In the last 90 days, insiders sold 329,000 shares of company stock valued at $117,458,920. 19.40% of the stock is owned by corporate insiders.

Moderna Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Article: When can a hold rating present a buying opportunity?

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.